Aravive (Aravive) Change In Receivables : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Aravive Change In Receivables?

Aravive's change in receivables for the quarter that ended in Sep. 2023 was $0.00 Mil. It means Aravive's Accounts Receivable stayed the same from Jun. 2023 to Sep. 2023 .

Aravive's change in receivables for the fiscal year that ended in Dec. 2022 was $0.00 Mil. It means Aravive's Accounts Receivable stayed the same from Dec. 2021 to Dec. 2022 .

Aravive's Accounts Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Aravive's Days Sales Outstanding for the three months ended in Sep. 2023 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aravive's liquidation value for the three months ended in Sep. 2023 was $-2.81 Mil.

Aravive Change In Receivables Historical Data

The historical data trend for Aravive's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Change In Receivables Chart

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Aravive Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Aravive (NAS:ARAV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aravive's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	2.756	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Aravive's accounts receivable are only considered to be worth 75% of book value:

Aravive's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.535	-	11.348	+	0.75 * 0	+	0.5 * 0
=	-2.81

Aravive Change In Receivables Related Terms

Thank you for viewing the detailed overview of Aravive's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (Aravive) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

VE11:Germany VE11:Germany

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Executives

Maria Carolina Petrini	officer: Chief Commercial Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller	officer: Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard	officer: Chief Financial Officer	322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove	officer: Chief Operating Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia	director, 10 percent owner	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre	officer: Chief Scientific Officer	C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk	director	225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah	officer: Chief Financial Officer	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala	officer: Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers	director	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc	director	319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman	director	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani	director, officer: President and CEO	3928 POINT EDEN WAY, HAYWARD CA 94545